Latest Recruitment News

Kore Potash has signed non-binding term sheets for a $2.2 billion financing package to develop its Kola Potash Project, marking a significant step toward construction. The company also progressed environmental assessments and strengthened government relations during Q2 2025.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

TerraCom reported steady coal sales for the June quarter despite softer thermal coal prices and weather disruptions, opting to withhold dividends while advancing key projects.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

GBM Resources has raised $13 million through a two-tranche placement, repaid $6.2 million in convertible debt, and completed a significant board restructure to accelerate exploration at its Drummond Basin gold projects.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

BauMart Holdings reports progress in AI-enhanced international recruitment, sustainable building materials development, and expansion into off-grid energy solutions, alongside a partial rights issue raising $180,000.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Future Metals NL has raised A$4.2 million and entered a strategic MOU with Zeta Resources to explore processing its Eileen Bore and Panton ores at the Savannah Mine plant, signalling a new phase of development amid rising PGM prices.